Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc. (Nasdaq: NAUT) is a Seattle-based proteomics company developing single-molecule protein sequencing technology for life-sciences research applications. The company entered the public markets through a business combination with ARYA Sciences Acquisition Corp III, a life-sciences-focused SPAC sponsored by Perceptive Advisors, a healthcare-oriented investment management firm. The merger agreement was announced in February 2021, with the transaction closing in June 2021; ARYA Sciences Acquisition Corp III had completed its IPO in 2020. The February 2021 Form 8-K filing with the SEC formally disclosed the proposed transaction terms to investors. Nautilus remains publicly traded in the biotechnology and proteomics sector. For complete filing history, ownership data, and deal analytics on NAUT and thousands of other SPAC transactions, sign up for full access at SpacDesk.